Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.18% | 38.86% | -17.89% | -43.64% | -70.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.36% | -28.93% | -51.93% | -43.64% | -31.63% |
| Change in Net Operating Assets | 1,172.35% | -186.03% | -1,084.62% | -235.26% | 92.57% |
| Cash from Operations | 38.99% | -19.59% | -42.90% | -72.18% | -45.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.31% | -82.45% | -5.93% | -6.14% | -8.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.47% | -82.52% | -44.17% | -44.28% | -43.64% |
| Foreign Exchange rate Adjustments | -60.87% | -514.55% | 102.69% | 80.55% | 93.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,559.60% | -478.96% | -74.67% | -87.40% | -90.18% |